Chemotherapy News and Research

Latest Chemotherapy News and Research

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Positive interim results from new bladder cancer therapy trial

Positive interim results from new bladder cancer therapy trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Study: Full access to personal medical record increases cancer patient's trust in physicians

Study: Full access to personal medical record increases cancer patient's trust in physicians

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Some cancer patients go without drugs because of high cost

Some cancer patients go without drugs because of high cost

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Study examines long-term GI complications in childhood cancer survivors

Study examines long-term GI complications in childhood cancer survivors

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.